Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis.

Corrado PelaiaClaudia CrimiAlida BenfanteMaria Filomena CaiaffaRaffaele CampisiClaudio CandiaGiovanna Elisiana CarpagnanoIsabella CarrieriMaria D'AmatoAikaterini DetorakiMaria Pia Foschino BarbaroNicola LombardoLuigi MacchiaAngelantonio MaglioElena MinennaSanti NolascoGiuseppe PaglinoFrancesco PapiaLuisa RicciardiNicola ScichiloneGiulia SciosciaGiuseppe SpadaroPasquale TondoSimona Uletta LionettiGiuseppe ValentiAlessandro VatrellaNunzio CrimiGirolamo Pelaia

Published in: Respirology (Carlton, Vic.) (2024)

Taken together, the results of this real-life clinical investigation indicate that benralizumab can induce a sustained remission on-treatment of SEA, especially in those patients with comorbid CRSwNP and reversible airflow limitation.

Keyphrases

chronic rhinosinusitis
rheumatoid arthritis
early onset
lung function
drug induced